These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8952858)
1. Expression of tissue-type plasminogen activator, plasminogen activator inhibitor and von Willebrand factor in the supernatant of endothelial cell cultures in response to the seeding of adenocarcinoma cell line HRT-18. Morganti M; Mittermayer C; Henze U; Carpi A; Sagripanti A Biomed Pharmacother; 1996; 50(8):373-5. PubMed ID: 8952858 [TBL] [Abstract][Full Text] [Related]
2. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. Marsh NA; Minter AJ; Chesterman CN Blood Coagul Fibrinolysis; 1990 Jun; 1(2):133-8. PubMed ID: 1966669 [TBL] [Abstract][Full Text] [Related]
3. Characterization of immortalized human umbilical and iliac vein endothelial cell lines after transfection with SV40 large T-antigen. van Leeuwen EB; Veenstra R; van Wijk R; Molema G; Hoekstra A; Ruiters MH; van der Meer J Blood Coagul Fibrinolysis; 2000 Jan; 11(1):15-25. PubMed ID: 10691096 [TBL] [Abstract][Full Text] [Related]
4. Extracellular and cell-associated localizations of plasminogen activators and plasminogen activator inhibitor-1 in cultured endothelium. Murata T; Nakashima Y; Yasunaga C; Maeda K; Sueishi K Exp Mol Pathol; 1991 Oct; 55(2):105-18. PubMed ID: 1936210 [TBL] [Abstract][Full Text] [Related]
5. Differences in coagulant and fibrinolytic activities of cultured human endothelial cells derived from omental tissue microvessels and umbilical veins. Speiser W; Anders E; Preissner KT; Wagner O; Müller-Berghaus G Blood; 1987 Mar; 69(3):964-7. PubMed ID: 3101768 [TBL] [Abstract][Full Text] [Related]
6. In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1. Pourtau J; Soria C; Paysant J; Vannier JP; Vasse M Blood Coagul Fibrinolysis; 1998 Oct; 9(7):609-15. PubMed ID: 9863709 [TBL] [Abstract][Full Text] [Related]
7. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression. Konkle BA; Ginsburg D J Clin Invest; 1988 Aug; 82(2):579-85. PubMed ID: 3136192 [TBL] [Abstract][Full Text] [Related]
8. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Blann AD; Dobrotova M; Kubisz P; McCollum CN Thromb Haemost; 1995 Aug; 74(2):626-30. PubMed ID: 8584997 [TBL] [Abstract][Full Text] [Related]
9. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. van Hinsbergh VW; Kooistra T; Scheffer MA; Hajo van Bockel J; van Muijen GN Blood; 1990 Apr; 75(7):1490-7. PubMed ID: 2107884 [TBL] [Abstract][Full Text] [Related]
10. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Ozoran K; Dügün N; Gürler A; Tutkak H; Tokgöz G Scand J Rheumatol; 1995; 24(6):376-82. PubMed ID: 8610223 [TBL] [Abstract][Full Text] [Related]
11. Binding of tissue plasminogen activator to human endothelial cells. Importance of the B-chain as a ligand. Cheng XF; Bäck O; Nilsson TK; Nylander Lundqvist E; Pohl G; Wallén P Biochem J; 1992 Oct; 287 ( Pt 2)(Pt 2):407-13. PubMed ID: 1332673 [TBL] [Abstract][Full Text] [Related]
12. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator. Schleef RR; Podor TJ; Dunne E; Mimuro J; Loskutoff DJ J Cell Biol; 1990 Jan; 110(1):155-63. PubMed ID: 2104856 [TBL] [Abstract][Full Text] [Related]
13. Ca2+ -regulated secretion of tissue-type plasminogen activator and von Willebrand factor in human endothelial cells. Knop M; Gerke V Biochim Biophys Acta; 2002 Nov; 1600(1-2):162-7. PubMed ID: 12445472 [TBL] [Abstract][Full Text] [Related]
14. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026 [TBL] [Abstract][Full Text] [Related]
15. Regulation of endothelial tissue plasminogen activator and plasminogen activator inhibitor type 1 synthesis by diacylglycerol, phorbol ester, and thrombin. Grulich-Henn J; Müller-Berghaus G Blut; 1990 Jul; 61(1):38-44. PubMed ID: 2117475 [TBL] [Abstract][Full Text] [Related]
16. Fibrinolytic and inflammatory processes in pleural effusions. Philip-Joët F; Alessi MC; Philip-Joët C; Aillaud M; Barriere JR; Arnaud A; Juhan-Vague I Eur Respir J; 1995 Aug; 8(8):1352-6. PubMed ID: 7489803 [TBL] [Abstract][Full Text] [Related]
17. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. Andreotti F; Roncaglioni MC; Hackett DR; Khan MI; Regan T; Haider AW; Davies GJ; Kluft C; Maseri A J Am Coll Cardiol; 1990 Dec; 16(7):1553-60. PubMed ID: 2123906 [TBL] [Abstract][Full Text] [Related]
18. Effects of heparin and endothelial cell growth supplement on haemostatic functions of vascular endothelium. Minter AJ; Dawes J; Chesterman CN Thromb Haemost; 1992 Jun; 67(6):718-23. PubMed ID: 1509415 [TBL] [Abstract][Full Text] [Related]
19. Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis. Sirén V; Kauhanen P; Carpén O; Luther M; Lepäntalo M; Vaheri A; Lassila R Blood Coagul Fibrinolysis; 2003 Jun; 14(4):369-77. PubMed ID: 12945879 [TBL] [Abstract][Full Text] [Related]
20. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Friedenberg WR; Roberts RC; David DE Am J Hematol; 1992 Aug; 40(4):283-9. PubMed ID: 1503083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]